close
Five Unicorns in the Race for a mRNA-based...

Five Unicorns in the Race for a mRNA-based...

Studies

390,00 excl. VAT

BioNTech, CureVac, Moderna Therapeutics, Translate Bio…. All of them are developing mRNA-based vaccine candidates against SARS-CoV-2 and have reached the clinical stage.
Four Unicorns in the Race for a mRNA-based Vaccine against Covid-19  develops mains assets and strengths for these companies.

Arcturus, BioNTech, CureVac, Moderna Therapeutics, Translate Bio….
These four biotech are the main state-of-the-art companies at the forefront in mRNA science.
All of them are now developing mRNA-based vaccine candidates against SARS-CoV-2
and have reached the clinical stage.

 

These programs could lead to short-term boosts for these companies’s shares. However, addressing epidemics is still a risky business. So far, it isn’t the most profitable area for companies and decision makers in health, industry and politics need a comprehensive overview of their businesses.

Let’s find out main assets and strengths of these companies in our latest report
« Five Unicorns in the Race for a mRNA-based Vaccine against Covid-19 »
(Updated September 2020)

The publication lists and develops in details:

• General informations on each company
(location, website, FTE, management….)
• Core Business and Corporate informations
• Recent Fundings and Financial Highlights
(grants, funding rounds, revenues, R&D expenses….)
• Pipeline
(target indications , mechanism of action, stage of development…)
• Orphan drug designations
• Ongoing Clinical Trials
(phase, status, start and completion date, planned enrollment…)
• Latest Developments
• Latest Scientific Publications

Want to have a look at this report ? Click to download sample pages

You want to buy the report ? Click on “ADD TO CART”

or Download the order form

To ensure a useful information and to facilitate the global overview you may need, each description of products, diseases and trials mentioned is completed with the most relevant and recent informations selected by our experts.


COMMENTS ARE OFF THIS POST